Abstract:

Objective  To explore the inflammatory effect and therapeutic results of Shexiang injection (SXI) in treating acute cerebral infarction(ACI) patients. Methods  46 patients with acute cerebral infarction were randomly divided into two groups, the control group (n=23, treated with normal drugs),and the SXI group (n=23,treated with SXI and normal drugs). Serum level of monocyte chemoattactant protein-1(MCP-1) and expression of polymorphnuclear (PMN)CD11b/CD18 were determined in acute period, on the 6th and 12th days of the disease course, and compared with that in 23 healthy persons. The therapeutic results were also compared after 30 days of treatment. Result  sSerum level of MCP-1 and expression of PMN-CD11b/CD18 in ACI patients were higher than in healthy persons (P<0.01). On the 6th day, the serum level of MCP-1 in the SXI group decreased to the healthy level (P>0.05), while in the control group it decreased but was higher than the healthy level(P<0.05), and on the 12th day it was decreased to the healthy level(P>0.05). Expression of PMN-CD11b/CD18 in the two groups increased at the highest level on the 6th day, and decreased significantly by the time of the 12th day (P<0.01); in the SXI group it decreased to the healthy level (P>0.05) while in control group it was also higher (P<0.05). After 30 days of treatment, the marked effective and curative rate in the SXI group was higher than that in the control group (χ2＝4.29, P<0.05). Conclusion  SXI could restrain the inflammatory injury of cerebral infarction, through which it improves the therapeutic effect.

Key words: Cerebral infarction； Shexiang injection；Monocyte chemoattactant protein-1；Polymorphnuclear CD11b/CD18； Therapeutic effect